Products

Below is a list of the treatments we currently offer via our Innovative Medicines Division. 
Please note: Not all treatments are available in all countries.

Lucentis Logo

 

Product Information

 Wet AMD, DME, Moderately severe to severe non-proliferative diabetic retinopathy (NPDR) and PDR, branch RVO or central RVO, CNV, Choroidal neovascularization secondary to pathologic myopia (PM), Retinopathy of prematurity (ROP)

Active Ingredients - Ranibizumab

Product Division - Novartis Pharmaceuticals

Subcategory - Antineovascularization agents